Ozay Pharmaceuticals

Ozay Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for post-surgical complications, specifically peritoneal adhesions. The company's lead candidate, OZY-001, is a first-in-class small molecule inhibitor of plasminogen activator inhibitor-1 (PAI-1) designed to prevent the formation of internal scars following abdominal or pelvic surgery. By maintaining the body's natural fibrinolytic activity, OZY-001 aims to reduce the incidence of bowel obstructions, chronic pain, and infertility associated with adhesions. Based in St. Louis, Missouri, Ozay Pharmaceuticals is supported by regional innovation hubs like BioGenerator. The company aims to address a significant unmet need in surgical recovery where no pharmacological standard of care currently exists.